Propanc Biopharma, Inc. (PPCB) Stock Price & Analysis
Propanc Biopharma, Inc. (PPCB) — MoonshotScore 28/100 (Weak band), calculated Nov 18, 2026. Price $1.78 (+3.19%), as of the Nov 20, 2026 trading session; market cap $1.87M.
Educational signal · not a buy or sell recommendation · How to read this
Propanc Biopharma, Inc. · PPCB
Propanc Biopharma, Inc. is a biopharmaceutical company focused on developing cancer treatments, particularly for pancreatic, ovarian, and colorectal cancers. Their lead product, PRP, is in the preclinical phase, designed to enhance the synergistic anti-cancer effects of multiple enzymes.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Propanc Biopharma (PPCB)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, a fragile balance sheet and an expensive valuation, though growth is only middling, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Flat; Momentum: Falling.
- Altman Z -27.02 · Piotroski F 2
Holding back: weak fundamentals, balance-sheet strain, a rich price, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 27 | Weak | |
| 30 | Weak | |
| 30 | Weak | |
| 28 | Weak | |
| 28 | Weak | |
| 28 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.78 | |
| Change on the day | +3.19% | |
| Market capitalisation | $1.87M | — |
| Shares traded on the day | 27.8K |
Price & events
Other perspectives
Council score for Propanc Biopharma (PPCB): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Propanc Biopharma (PPCB), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Propanc Biopharma, Inc. (PPCB) is the company analyzed here. It employs 2 people. The market values it at $1.87M.
What are the financial strengths and risks for Propanc Biopharma (PPCB)?
Short answer · as of
What is holding it back is weak fundamentals, balance-sheet strain, a rich price, weak price trend. The distress and quality screens read Altman Z -27.02 · Piotroski F 2. Trailing ratios: current ratio 2.47.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -27.02 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
How does Propanc Biopharma compare with its peers?
Short answer
Propanc Biopharma's score ranks 12th of 12 in the bounded comparison shown, against 11 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.45 Nov 19, 2026 | $475M | 91 5-pillar Nov 18, 2026 | |
| $8.76 Nov 20, 2026 | $521M | 91 5-pillar Nov 18, 2026 | |
| $2.90 Nov 20, 2026 | $245M | 90 5-pillar Nov 18, 2026 | |
| $40.09 Nov 20, 2026 | $755M | 88 5-pillar Nov 18, 2026 | |
| $15.47 Nov 20, 2026 | $86.6M | 82 5-pillar Nov 18, 2026 | |
| $10.92 Nov 20, 2026 | $99.3M | 82 5-pillar Nov 18, 2026 | |
| $3.69 Nov 19, 2026 | $160M | 72 5-pillar Nov 18, 2026 | |
| $1.84 Nov 20, 2026 | $174M | 69 5-pillar Nov 18, 2026 | |
| $9.19 Nov 20, 2026 | $540M | 68 5-pillar Nov 18, 2026 | |
| $10.02 Nov 20, 2026 | $148M | 61 5-pillar Nov 18, 2026 | |
| $6.11 Nov 20, 2026 | $488M | 60 5-pillar Nov 18, 2026 | |
| Propanc Biopharma (PPCB) — this page | $1.78 | $1.87M | 28 |
| $0.40 Nov 20, 2026 | $27.2M | — Model unavailable |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 12
- Identified insiders
- 3
- Purchases
- 0
- Sales
- 0
- Other transactions
- 12
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held PPCB in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported PPCB in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Propanc Biopharma (PPCB)?
- Propanc Biopharma Reports Quarterly Financial Results
- Propanc Biopharma Reports Preclinical Data with PRP & PRP plus TGF-β Inhibitor on TGF-β Pathway in Pancreatic Cancer
- Propanc Biopharma Advances Bioanalytical and Immunogenicity Assay Development for Phase 1b Study
- Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients
Propanc Biopharma Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the PPCB research dossier (written Mar 16, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for PPCB?
PPCB carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Propanc Biopharma, Inc. is a biopharmaceutical company focused on developing cancer treatments, particularly for pancreatic, ovarian, and colorectal cancers.
Is PPCB a good stock to buy?
Stock Expert AI does not rate PPCB buy, sell or hold. Propanc Biopharma, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the PPCB stock price today?
The last price recorded for Propanc Biopharma, Inc. (PPCB), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
How does Propanc Biopharma, Inc. manage the risk of clinical trial failures?
Propanc Biopharma, Inc. attempts to mitigate the risk of clinical trial failures through rigorous preclinical testing and careful selection of clinical trial endpoints.
What are the key factors to evaluate for PPCB?
Propanc Biopharma, Inc. (PPCB) holds a MoonshotScore in the low range. The potential market size is dependent on the specific cancer subtypes targeted. Not financial advice.
How frequently does PPCB data refresh on this page?
PPCB's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven PPCB's recent stock price performance?
Propanc Biopharma, Inc. (PPCB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel enzyme-based therapy (PRP) with a unique mechanism of action. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PPCB overvalued or undervalued right now?
Propanc Biopharma, Inc. (PPCB) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PPCB before investing?
Before investing in Propanc Biopharma, Inc. (PPCB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 10 figures on this page — 6 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com